Molecular Partners AG ADR (MOLN)

NASDAQ
Currency in USD
3.890
+0.070(+1.83%)
Closed·
After Hours
3.900+0.010(+0.257%)
·
MOLN Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MOLN is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
3.8903.890
52 wk Range
3.36012.220
Key Statistics
Edit
Prev. Close
3.82
Open
3.89
Day's Range
3.89-3.89
52 wk Range
3.36-12.22
Volume
285
Average Volume (3m)
10.42K
1-Year Change
-64.67%
Book Value / Share
3.93
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
MOLN Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.731
Upside
+175.87%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Molecular Partners AG ADR News & Analysis

Show more

Molecular Partners AG Company Profile

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in preclinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and Radio-DARPin Therapy to treat ovarian disease. In addition, the company develops MP0621, a molecular partners’ first Switch-DARPin program, which is in preclinical trial designed to induce killing of hematopoietic stem cells (HSCs) as a next-generation conditioning regimen for HSC transplantation (HSCT); and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Compare MOLN to Peers and Sector

Metrics to compare
MOLN
Peers
Sector
Relationship
P/E Ratio
−1.8x−2.1x−0.5x
PEG Ratio
−0.42−0.010.00
Price/Book
0.8x6.1x2.6x
Price / LTM Sales
47.9x4.8x3.0x
Upside (Analyst Target)
171.8%40.0%52.6%
Fair Value Upside
Unlock8.5%8.8%Unlock

Analyst Ratings

3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.731
(+175.87% Upside)

Earnings

Latest Release
May 15, 2025
EPS / Forecast
-0.5419 / -0.4211
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

0.175
NCL
-9.36%
0.255
CETY
-5.56%
3.8000
SHPH
+5.56%
0.0574
WLGS
-1.03%
0.330
HSDT
-8.33%

FAQ

What Is the Molecular Partners AG (MOLN) Share Price Today?

The live Molecular Partners AG share price today is 3.89.

What Stock Exchange Does Molecular Partners AG (MOLN) Trade On?

Molecular Partners AG is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Ticker (Stock Symbol) for Molecular Partners AG?

The stock symbol (also called a 'ticker') for Molecular Partners AG is "MOLN."

What Is the Current Molecular Partners AG Market Cap?

As of today, Molecular Partners AG market capitalisation is 130.58M.

What Is Molecular Partners AG's (MOLN) Earnings Per Share (TTM)?

The Molecular Partners AG EPS -1.70 (Trailing Twelve Months).

When Is the Next Molecular Partners AG Earnings Date?

Molecular Partners AG's next earnings report will be released on 24 Aug 2025.

Is MOLN a Buy or Sell From a Technical Analyst Perspective?

Based on today's Molecular Partners AG moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Molecular Partners AG Stock Split?

Molecular Partners AG has split 0 times. (See the MOLN stock split history page for full effective split date and price information.)

How Many Employees Does Molecular Partners AG Have?

Molecular Partners AG currently has 159 employees.

What is the current trading status of Molecular Partners AG (MOLN)?

As of 21 Jun 2025, Molecular Partners AG (MOLN) is trading at a price of 3.89, with a previous close of 3.82. The stock has fluctuated within a day range of 3.89 to 3.89, while its 52-week range spans from 3.36 to 12.22.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.